| ¼ò½é£º   ²¿·ÝÖÐÎİ¢ÅÁ³Ëû°·´¦·½×ÊÁÏ£¨½ö¹©²Î¿¼£©ÉÌÆ·Ãû£ºERLEADA
 Ó¢ÎÄÃû£ºApalutamide
 ÖÐÎÄÃû£º°¢ÅÁ³Ëû°·Æ¬
 Éú²úÉÌ£ºÑîÉÖÆÒ©
 Ò©Æ·¼ò½é
 Erleada£¨Apalutamide£¬¥¢©`¥ê©`¥ÀåV£©ÊÇÓÉÇ¿ÉúÆìϵÄÑîÉÉúÎï¼¼Êõ(Janssen Biotech)¹«Ë¾×ÔÖ÷Ñз¢µÄÐÂÒ»´ú¿¹°©ÐÂÒ©£¬ÓÃÓÚÖÎÁÆ·Ç×ªÒÆÐÔÈ¥ÊÆµÖ¿¹Ç°ÁÐÏÙ°©(non-metastatic,castration-resistant prostate cancer,NM-CRPC)µÄ´¦·½Ò©¡£
 ¥¢©`¥ê©`¥ÀåV60mg
 Ò©ÓÃÀà±ðÃû³Æ
 ǰÁÐÏÙ°©ÖÎÁƼÁ
 Åú×¼ÈÕÆÚ£º2019Äê5ÔÂ
 É̘ËÃû
 ERLEADA Tablets
 Ò»°ãÃû£º¥¢¥Ñ¥ë¥¿¥ß¥É£¨JAN£©¡¢Apalutamide£¨JAN£©
 »¯Ñ§Ãû£º4-£û7-£Û6-Cyano-5-£¨trifluoromethyl£©pyridin-3-yl£Ý-
 8-oxo-6-thioxo-5,7-diazaspiro£Û3.4£Ýoctan-5-yl£ý-
 2-fluoro-N-methylbenzamide
 ·Ö×Óʽ£ºC21H15F4N5O2S
 ·Ö×ÓÁ¿£º477.43
 »¯Ñ§˜‹Ôìʽ£º
 ÐÔ×´£º
 °×É«ÖÁµ»ÆÉ«·ÛÄ©
 Èܽâ¶È£º
 ËüÈÝÒ×ÈÜÓÚÒÒëæ, ΢ÈÜÓÚÒÒ´¼
 ¼¸ºõ²»ÈÜÓÚË®¡£
 ÈÛµã: Ô¼ 194 ~ 196°c
 ·ÖÇøÏµÊý: LogP=2.89(1-octanol/PH 7.0Á×ËáÑλº³åÒº)
 ²Ù×÷×¢ÒâÊÂÏî
 Çë·ÅÔÚ¶ùͯ½Ó´¥²»µ½µÄµØ·½¡£
 ²»ÒªÔÚÅÄÉãǰ´Ó PTP ¹¤×÷±íÖе¯³ö¡£
 Åú×¼Ìõ¼þ
 ÖÆ¶¨Ò©Æ··çÏÕ¹ÜÀí¼Æ»®²¢¼ÓÒÔʵʩ¡£
 Ò©ÓÃÒ©Àíѧ
 1. ×÷ÓûúÖÆ
 °¢ÅÁËþ°·, ÒÔ¼°ÒÖÖÆÓëÐÛ¼¤ËØÊÜÌå(AR)ÅäÌå½áºÏλµãµÄ½áºÏ, ÒÖÖÆARµÄϸ°ûºËÇ¨ÒÆ, Óë AR µÄת¼Òò×Ó½áºÏÇøÓò½áºÏ, ͨ¹ýÒÖÖÆÄ¿±ê»ùÒòµÄת¼, ͨ¹ýARÒÖÖÆÐźÅ, ±»ÈÏΪ¿ÉÒÔÒÖÖÆÐÛ¼¤ËØÒÀÀµÐÔÖ×ÁöµÄÉú³¤¡£
 2. ¿¹Ö×Áö×÷ÓÃ
 °¢ÅÁËû°·, ÔÚÌåÍâÊÔÑéÖÐ, ÒÖÖÆÈËǰÁÐÏÙ°©ÑÜÉúVCaPϸ°ûϵµÄÔöÖ³¡£´ËÍâ, ÔÚÌåÄÚÊÔÑéÖÐ, ÏÔʾÖ×ÁöÉú³¤ÒÖÖÆ×÷ÓõÄÈ¥ÁôÑÏÖØ¸´ÔÓÐÍÃâÒßȱÏÝ(SCID)СÊóƤÏÂÒÆÖ²µÄÈËǰÁÐÏÙ°©ÑÜÉúLNCaPϸ°ûϵ±íʾ¡£
 ÊÊÓ¦Ö¢
 ¡ðÎÞ¸ô×ªÒÆµÄÈ¥ÊÆµÖ¿¹ÐÔǰÁÐÏÙ°©
 ¡ð¾ßÓÐÔ¶´¦×ªÒƵÄǰÁÐÏÙ°©
 Ó÷¨ÓëÓÃÁ¿
 ͨ³£Çé¿öÏÂ, ³ÉÈËÿÌì¿Ú·þ240ºÁ¿Ë¡£ÁíÍâ, ¸ù¾Ý»¼ÕßµÄÇé¿öÊʵ±¼õÉÙ¼ÁÁ¿¡£
 ÁÙ´²½á¹û
 ¹ú¼ÊÁªºÏµÚÈý½×¶ÎÊÔÑé(ARN-509-003 ÊÔÑé)
 ǰÁÐÏÙÌØÒìÐÔ¿¹Ô(PSA)¼Ó±¶Ê±¼äΪ10¸öÔ»ò¸üÉÙ.1)È¥µôÄÍҩǰÁÐÏÙ°©×¢.2) »¼ÕßûÓÐÔ¶³Ì×ªÒÆ, ÔÚÐÛ¼¤ËØÈ¥³ýÖÎÁÆ(ADT)µÄ×éºÏÏÂ, ½øÐÐË«Ã¤Ëæ»úÊÔÑéµÄÄ¿µÄÊDZȽÏÕâÖÖÒ©ÎïºÍ°²Î¿¼Á(ÀýÈç1207µÄÁÆÐ§·ÖÎö, 55ÈÕ±¾²¡Àý)¡£¸Ã×é240MGÿÌì¿Ú·þÒ»´Î¡£Ö÷ÒªÆÀ¼ÛÏîÄ¿ÉèÖÃΪ·Ç×ªÒÆÐÔÉú´æÆÚ(MFS)¡£¾¹ý¶ÔMFSµÄ×îÖÕ·ÖÎö(·ÖÎöʼþ419), ÖÐλÊý, ÔÚ°²Î¿¼Á×é15.70¸öÔÂÖÐ, ´úÀí×é400.51¸öÔÂÏÔʾ, ÔÚ´úÀí×éÖÐ, ÓÐͳ¼ÆÑ§ÒâÒåÉϵÄÀ©Õ¹(ΣÏÕ±ÈÂÊ: 0.297, 95%ÖÃÐÅÇø¼ä: 0.244~0.362, °´²ã·ÖÁеÄÈÕÖ¾ÅÅÃû²âÊÔ: p<0.0001)¡£
 ¸½×¢ 1)
 ADTÔÚÖ´ÐÐʱÖÁÉÙÒª²âÁ¿PSAÖµµÄÈý±¶, ¼ÆËã³öPSAÖµµÄ»¼Õß·±¶Ê±¼äΪ10¸öÔ»ò¸ü¶Ì¡£
 ¸½×¢ 2)
 (1) ѪÇåØºÍªÖµÐ¡ÓÚ50ng/dl,
 (2) PSA Öµ´óÓÚ2.0ng/ml, ²¢ÇÒ
 (3) Èý´Î¹Û²ìµ½ÔÚ²âÁ¿Ê±¼ä³¬¹ýÒ»ÖܵÄÇé¿öÏÂPSAÖµµÄÔö¼Ó, ²¢¶Ô»¼ÓÐÈ¥É˵ÄÄÍҩǰÁÐÏÙ°©»¼Õß½øÐÐÁËÈý´Î¹Û²ì¡£´ËÍâ, ¹ÇÅèÁܰͽá×ªÒÆÐ¡ÓÚ2ÀåÃ×µÄ÷ŹؽڷÖÖ§ÏÂÊôµÄ»¼Õß±»ÔÊÐíÄÉÈë¡£
 °ü×°
 56Ƭ(28Ƭ x2)
 ÖÆÔìÉ̺ͷÖÏúÉÌ:
 ÑîÉÒ©ÒµÓÐÏÞ¹«Ë¾
 ÌáЯ£º
 ÈÕ±¾ÐÂËaÖêʽ»áÉç
 ×¢£ºÒÔÉÏÖÐÎIJ»¹»ÍêÕû£¬Ê¹ÓÃÕßÒÔÔ´¦·½×ÊÁÏΪ׼¡£
 ÍêÕû˵Ã÷¸½¼þ£º
 http://www.janssenpro.jp/cs/Satellite?pagename=jpro/BlobDspBody&c=simage&cid=1402077117805
 Erleada Tablets(apalutamide,¥¢©`¥ê©`¥ÀåV60mg, °¢ÅÁ³Ëû°·Æ¬)
 Aleader Tablet 60 mg Product Overview
 Product Name: Aleader Tablet 60mg
 Common Name: Appartamide
 Efficacy/effect: castration resistant prostate cancer without distant metastasis
 Dosage: Usually, for adults, orally administered 240 mg once a day as an apaltamide. The dose should be reduced according to the patient's condition.
 Production approval date: March 26, 2019
 Reference price list price: May 22, 2019
 |